Search

Your search keyword '"Romano, Alessandra"' showing total 314 results

Search Constraints

Start Over You searched for: Author "Romano, Alessandra" Remove constraint Author: "Romano, Alessandra" Publication Year Range Last 3 years Remove constraint Publication Year Range: Last 3 years
314 results on '"Romano, Alessandra"'

Search Results

2. 'Una Faccia, Una Razza': Similarities, Differences, and Parallels in Adult Education Policy Development in Greece and Italy

3. Innovation as Socially Shared Practice: The Contribution of the Teaching and Learning Center

4. Does It Really Take a Village to Raise a Child? Reflections on the Need for Collective Responsibility in Inclusive Education

5. Psychological distress and suicidal ideation in Sicilian Medical Students: The SMS-ME project

6. Decoding the historical tale: COVID-19 impact on haematological malignancy patients—EPICOVIDEHA insights from 2020 to 2022

7. A Methodological Framework to Cultivate Transformative Learning in Faculty Development

8. Seismic Base Isolation of a Strategic Historic Masonry Building

9. Innovation as socially shared practice: the contribution of the Teaching and Learning Center

15. MOLNUPIRAVIR COMPARED TO NIRMATRELVIR/RITONAVIR FOR COVID-19 IN HIGH-RISK PATIENTS WITH HAEMATOLOGICAL MALIGNANCY IN EUROPE. A MATCHED-PAIRED ANALYSIS FROM THE EPICOVIDEHA REGISTRY

16. Decoding the historical tale: COVID-19 impact on haematological malignancy patients—EPICOVIDEHA insights from 2020 to 2022

17. CXCL12/CXCR4 axis supports mitochondrial trafficking in tumor myeloma microenvironment

18. In-vitro NET-osis induced by COVID-19 sera is associated to severe clinical course in not vaccinated patients and immune-dysregulation in breakthrough infection

20. IgG-k/IgG-λ Para-Osseous Plasmacytoma Relapsed as Soft-Tissue Plasmacytoma with IgA-k Immunophenotype: A Case Report and Review of the Literature on Related Biochemical Aspects.

21. A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study

22. How Do Attitudes and Self-Efficacy Predict Teachers’ Intentions to Use Inclusive Practices? A Cross-National Comparison Between Canada, Germany, Greece, Italy, and Switzerland

23. Baseline IgM Amounts Can Identify Patients with Poor Outcomes: Results from a Real-Life Single-Center Study on Classical Hodgkin Lymphoma

27. Decoding the historical tale: COVID-19 impact on haematological malignancy patients-EPICOVIDEHA insights from 2020 to 2022

28. Effectiveness, safety, and tolerability of delayed dexamethasone, rituximab, and cyclophosphamide as first-line treatment in patients with Waldenström macroglobulinemia: data from the Sicilian Myeloma Network.

29. Enhanced Antitumor Activity by the Combination of Dasatinib and Selinexor in Chronic Myeloid Leukemia.

30. Belantamab Mafodotin and Relapsed/Refractory Multiple Myeloma: This Is Not Game Over.

31. Comprehensive analysis of clinical outcomes, infectious complications and microbiological data in newly diagnosed multiple myeloma patients: a retrospective observational study of 92 subjects.

32. High-dose chemotherapy and autologous stem cell transplant as first salvage treatment for relapsed or refractory Hodgkin Lymphoma in the era of PET-adapted strategies

33. Patients' Perception of Usability and Utility of a Digital Health Tool for Electronic Patient-Reported Outcomes Monitoring in Real-Life Hematology Practice: Evidence from the Gimema-Alliance Platform

34. Engagement of Mesenchymal Stromal Cells in the Remodeling of the Bone Marrow Microenvironment in Hematological Cancers

36. Multiple Myeloma in 2023 Ways: From Trials to Real Life

37. Engagement of Mesenchymal Stromal Cells in the Remodeling of Bone Marrow Microenvironment in Hematological Cancers

38. Measuring collective efficacy for inclusion in a global context.

39. Potential clinical impact of T-cell lymphocyte kinetics monitoring in patients with B cell precursors acute lymphoblastic leukemia treated with blinatumomab: a single-center experience

40. Breakthrough infection after SARS-CoV-2 vaccines in patients with hemoglobinopathies and blood-transfusion management: a single Center experience

41. IBCL-057 Incidence and Features of SARS-CoV-2 Breakthrough Infection in the Hematological Conditions After Tixagevimab-Cilgavimab Prophylaxis

42. Efficacy and safety of tixagevimab‐cilgavimab versus SARS‐CoV‐2 breakthrough infection in the hematological conditions

43. POSTER: IBCL-057 Incidence and Features of SARS-CoV-2 Breakthrough Infection in the Hematological Conditions After Tixagevimab-Cilgavimab Prophylaxis

44. Lenalidomide plus Dexamethasone Combination as First-Line Oral Therapy of Multiple Myeloma Patients: A Unicentric Real-Life Study

48. PB2534: SARS-COV-2 IMMUNIZATION AFTER VACCINES IN PATIENTS WITH HEMOGLOBINOPATHY: A SINGLE CENTER EXPERIENCE

50. P1558: PROPHYLAXIS WITH TIXAGEVIMAB-CILGAVIMAB IN SINGLE-CENTER EXPERIENCE CAN REDUCE SEVERE COMPLICATIONS RELATED TO SARS-COV-2 INFECTION IN HEMATOLOGICAL PATIENTS

Catalog

Books, media, physical & digital resources